MIRA Pharmaceuticals, Inc.
MIRA News Today: Stay Updated with the Latest MIRA Pharmaceuticals, Inc. News in Real Time
Find MIRA news now at Meyka AI. Stay informed with the latest MIRA Pharmaceuticals, Inc. stocks updates, including price news, market analysis, and expert insights.

CHM.CN Waverunner Capital (CNQ) +900.00% to C$0.05 on 08 Apr 2026: watch liquidity
CHM.CN stock jumps 900.00% to C$0.05 on 08 Apr 2026; fast-moving, low-liquidity trade warrants caution

RLBD Real Brands (PNK) volume spike 08 Apr 2026: $0.00001 traders watch
RLBD stock sees a volume spike on 08 Apr 2026 at $0.00001; high relative volume and oversold RSI inform short-term setups

April 8: US 100% Drug Tariffs Start July 31; Onshoring Deals in Focus
US drug tariffs start on 31 July 2026. Learn how Section 232 tariffs on patented drugs and APIs could affect Singapore costs, supply chains, and investor strategy.

3271.T The Global Ltd. JPX +26.87% after hours 08 Apr 2026: volume spike may signal trend shift
3271.T stock jumps to JPY 1275 after hours on 08 Apr 2026 with heavy volume; read our high-volume mover analysis

AVAV AeroVironment NASDAQ close $186.85 on 07 Apr 2026: AI defense upside 38.68%
AVAV stock closed $186.85 on 07 Apr 2026; Meyka AI projects a $259.13 12-month target for a 38.68% upside

ALPHAGEO.BO Alphageo (India) BSE up 20% pre-market 08 Apr 2026: 30% to INR 291.94
Pre-market: ALPHAGEO.BO stock up 20% to INR 224.40 on 08 Apr 2026; Meyka AI sees 30.10% upside to INR 291.94

3E2.BE Etsy, Inc. (BER) up 1.65% in market hours: Oversold bounce setup
3E2.BE stock trades at €47.92 on 08 Apr 2026; short-term oversold bounce possible vs 200-day SMA — Meyka AI forecast and grade

Evercore ISI Maintains Outperform on Zillow Group, Inc. Class A (ZG) March 2026
Evercore ISI maintained Outperform on Zillow Group (ZG) March 17, 2026 — ZG analyst rating noted with market reaction and Meyka grade B+

Citigroup Maintains Buy on AMZN (Amazon.com, Inc.) March 17, 2026
Citigroup maintains Buy on AMZN; our AMZN analyst rating coverage reviews price targets and investor implications